MA49141A - Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau - Google Patents

Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau

Info

Publication number
MA49141A
MA49141A MA049141A MA49141A MA49141A MA 49141 A MA49141 A MA 49141A MA 049141 A MA049141 A MA 049141A MA 49141 A MA49141 A MA 49141A MA 49141 A MA49141 A MA 49141A
Authority
MA
Morocco
Prior art keywords
pyrrolopyridine
treatment
skin conditions
aniline compounds
aniline
Prior art date
Application number
MA049141A
Other languages
English (en)
Inventor
Matthew Duncton
John Kincaid
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of MA49141A publication Critical patent/MA49141A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA049141A 2017-05-19 2018-05-18 Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau MA49141A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US201862663202P 2018-04-26 2018-04-26

Publications (1)

Publication Number Publication Date
MA49141A true MA49141A (fr) 2020-03-25

Family

ID=62620966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049141A MA49141A (fr) 2017-05-19 2018-05-18 Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau

Country Status (11)

Country Link
US (2) US11161845B2 (fr)
EP (1) EP3624796A1 (fr)
JP (1) JP7212956B2 (fr)
KR (1) KR102642411B1 (fr)
CN (1) CN111065393B (fr)
AU (1) AU2018270295B2 (fr)
CA (1) CA3063536A1 (fr)
IL (1) IL270752B (fr)
MA (1) MA49141A (fr)
MX (2) MX2019013561A (fr)
WO (1) WO2018213810A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063535A1 (fr) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Composes heteroaromatiques-aniline fusionnes pour le traitement de troubles dermiques
WO2018213810A1 (fr) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
EP4233834A3 (fr) * 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
WO2020106303A1 (fr) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
CN116601152A (zh) * 2020-09-24 2023-08-15 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺类化合物治疗认知功能障碍
US20240228480A1 (en) * 2021-01-21 2024-07-11 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds
EP4281055A1 (fr) * 2021-01-21 2023-11-29 NFlection Therapeutics, Inc. Formes cristallines d'un composé de pyrrolopyridine-aniline
CN118591373A (zh) * 2021-11-23 2024-09-03 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的制剂
US20230293463A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of cutaneous neurofibromas with Mirdametinib

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
WO2006083979A2 (fr) 2005-02-02 2006-08-10 Nexgenix Pharmaceuticals, L.L.C. Traitement local des neurofibromes
NZ565255A (en) * 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
JP5448818B2 (ja) 2006-08-21 2014-03-19 ジェネンテック， インコーポレイテッド アザベンゾフラニル化合物および使用方法
WO2008024724A1 (fr) 2006-08-21 2008-02-28 Genentech, Inc. Composés aza-benzothiophényle et leurs procédés d'utilisation
JP2010508307A (ja) 2006-10-31 2010-03-18 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
EP2099796B1 (fr) * 2006-11-30 2011-06-01 Genentech, Inc. Composés azaindolyliques et procédés d'utilisation de ceux-ci
US20080312307A1 (en) 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009082687A1 (fr) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines et procédés d'utilisation
EP2240494B1 (fr) 2008-01-21 2016-03-30 UCB Biopharma SPRL Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2012040636A2 (fr) 2010-09-24 2012-03-29 The Broad Institute, Inc. Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2018213810A1 (fr) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau

Also Published As

Publication number Publication date
IL270752A (en) 2020-01-30
JP2020520995A (ja) 2020-07-16
CN111065393B (zh) 2023-08-18
IL270752B (en) 2022-06-01
US20220033399A1 (en) 2022-02-03
WO2018213810A1 (fr) 2018-11-22
EP3624796A1 (fr) 2020-03-25
MX2022001697A (es) 2022-04-07
US20200165243A1 (en) 2020-05-28
KR20200013239A (ko) 2020-02-06
MX2019013561A (es) 2022-02-09
US12065439B2 (en) 2024-08-20
AU2018270295B2 (en) 2022-03-03
KR102642411B1 (ko) 2024-02-28
AU2018270295A1 (en) 2019-12-05
CN111065393A (zh) 2020-04-24
JP7212956B2 (ja) 2023-01-26
US11161845B2 (en) 2021-11-02
CA3063536A1 (fr) 2018-11-22

Similar Documents

Publication Publication Date Title
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
MA52575A (fr) Pansement pour le traitement de la peau endommagée
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MA45192A (fr) Traitement d'association
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
ZA202006610B (en) Compositions for the treatment of skin conditions
MA55143A (fr) Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
ZA202007055B (en) Compositions for the treatment of skin conditions
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
MA54741A (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA51738A (fr) Composés pour le traitement de la douleur
MA45552A (fr) Compositions destinées au traitement de l'amylose
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
MA53664A (fr) Composés destinés au traitement de certaines leucémies
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies
MA53817A (fr) Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv
MA55144A (fr) Composés naphthyridinone-aniline destinés au traitement d'affections de la peau
MA47595A (fr) Méthodes de traitement d'affections neurodégénératives
MA55141A (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques